Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix Pharmaceuticals announced a collaboration with Ekalia, a JV of IBA and Framatome, to establish scalable U.S. production of astatine-211, a scarce alpha-emitting isotope for targeted alpha therapy. The deal secures long-term, priority isotope access for Telix's alpha therapy pipeline, including TLX102-Tx in glioblastoma and leptomeningeal disease. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site near Philadelphia, with a framework to evaluate additional RLS installations as demand develops.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.